Prof. Reuven Stein

Prof. Stein showed in the past that CD38 in the tumor microenvironment (TME) regulates glioma and melanoma progression. Latest results suggest that targeting CD38 by small inhibitors can be used as a new therapeutic approach to treat cancers.

Prof. Stein’s team have proven this concept using CD38 small molecule CD38 inhibitors and are currently developing leads that will be used as drugs.    

Relevant research topics:
1. The role of CD38 in the glioma TME on glioma progression
2. Distinctive role of microglia and macrophages in glioma progression.
3. The role of CD38 in the TME on primary and metastatic melanoma focusing on cancer associated fibroblasts.
5. The role of CD38 in astrocytes on brain tumors. 


Contact Information:

Prof. Reuven Stein PhD
Faculty of Life sciences






Tel Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel
UI/UX Basch_Interactive